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Abstract
Early detection of fibrosis progression is of major relevance for the diagnosis and management of patients with liver disease.
This study was designed to find non-invasive biomarkers for fibrosis in a clinical context where this process occurs rapidly,
HCV-positive patients who underwent liver transplantation (LT). We analyzed 93 LT patients with HCV recurrence, 41 non-LT
patients with liver disease showing a fibrosis stage F$1 and 9 patients without HCV recurrence who received antiviral
treatment before LT, as control group. Blood obtained from 16 healthy subjects was also analyzed. Serum samples were
fractionated by ion exchange chromatography and their proteomic profile was analyzed by SELDI-TOF-MS. Characterization
of the peptide of interest was performed by ion chromatography and electrophoresis, followed by tandem mass
spectrometry identification. Marked differences were observed between the serum proteome profile of LT patients with
early fibrosis recurrence and non-recurrent LT patients. A robust peak intensity located at 5905 m/z was the distinguishing
feature of non-recurrent LT patients. However, the same peak was barely detected in recurrent LT patients. Similar results
were found when comparing samples of healthy subjects with those of non-LT fibrotic patients, indicating that our findings
were not related to either LT or HCV infection. Using tandem mass-spectrometry, we identified the protein peak as a C-
terminal fragment of the fibrinogen a chain. Cell culture experiments demonstrated that TGF-b reduces a-fibrinogen mRNA
expression and 5905 m/z peak intensity in HepG2 cells, suggesting that TGF-b activity regulates the circulating levels of this
protein fragment. In conclusion, we identified a 5.9 kDa C-terminal fragment of the fibrinogen a chain as an early serum
biomarker of fibrogenic processes in patients with liver disease.
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Introduction
Early detection of fibrosis progression and the development of
portal hypertension is of major relevance in the prognosis and
treatment of patients with chronic liver disease [1]. Indeed, early
recognition of subjects prone to develop these alterations may
allow prompt initiation of therapeutic interventions. Therefore,
identification of noninvasive biomarkers related to the activation
of the fibrogenic process is of major relevance, particularly in those
subjects with sustained liver injury [2]. However, despite the
numerous attempts to uncover such molecules, this objective has
resulted elusive. This is likely related to the natural history of liver
disease. With the exception of fulminant hepatic failure, liver
disease is an insidious process in which clinical detection and
symptoms of hepatic decompensation may occur weeks, months or
many years after the onset of injury, and healing may occur
without clinical detection [3]. However, in particular clinical
circumstances, i.e. patients infected with the hepatitis C virus
(HCV), submitted to liver transplantation (LT), it is possible to
expect recurrence of hepatic fibrosis and portal hypertension to
occur within a short period of time [4]. Thus, these patients
constitute a population particularly suitable to identify noninvasive
markers of early fibrogenesis.
The current investigation took advantage of the faster develop-
ment of hepatic fibrosis in HCV-positive LT patients. Serum
samples were collected shortly after LT and high-throughput
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proteomic techniques were used to ascertain whether the
proteomic pattern of these samples differs from the proteomic
pattern expression obtained from serum samples of non-infected
LT patients. Ultimately, the investigation was aimed to identify
early circulating serum biomarkers of active fibrogenesis in
patients with liver disease.
Materials and Methods
Patients
One hundred and nineteen patients admitted to the Liver Unit
to undergo a liver biopsy from June 2001 to January 2006 were
prospectively considered for this study. Exclusion criteria were
presence of ascites, chronic kidney failure in hemodyalisis and
moderate or severe acute graft rejection during the first three
months, biliary complications or antiviral treatment during the
first year after LT in the case of LT recipients. In addition 16
healthy volunteers were also included in the study.
The design of the study was two folded: first we assessed
whether the serum proteomic profile of recurrent HCV-LT
patients differs from that of non-recurrent HCV-LT patients. The
serum proteomic profile and routine liver and renal function tests
were initially analyzed in a training set of 10 HCV-RNA recurrent
LT patients 6 months post LT that showed a fibrosis stage F$1 at
1 year after LT. Paired hepatic venous pressure gradient (HVPG)
determination was also available in 7 of these patients. The control
group consisted in 9 patients without HCV-RNA recurrence, who
underwent antiviral treatment before LT and achieve sustained
virological response. In addition, serum samples were also
collected from 41 non-LT patients with advanced liver disease.
The HCV or hepatitis B virus (HBV) was present in 8 and 3 of
these patients, respectively, whereas the etiology of liver disease
was other than viral in the remaining (9 nonalcoholic steatohe-
patitis, NASH; 10 alcoholic liver disease, ALD; 4 autoimmune
hepatitis, AH; and 7 cryptogenic). Thereafter, the results were
validated in a test set of 83 HCV recurrent LT patients. Serum
samples were also collected 6 months post-transplantation and the
proteomic profile was evaluated along with liver and renal
function tests. HVPG measurement in 53 of these patients was
also performed.
Liver Biopsies and paired HVPG measurements
Percutaneous and transjugular liver biopsies and HVPG
measurements were performed as we have previously described
[5]. Fibrosis stage was scored using the Scheuer classification: no
fibrosis (F0), minimal portal fibrosis (F1), periportal fibrosis (F2),
fibrosis beyond the portal tract making septums (F3) and cirrhosis
(F4) [6].
Serum fractionation
See (Data S1).
High-throughput proteomic processing of serum
samples
Protein profiling was performed by surface-enhanced laser
desorption/ionization time-of-flight mass spectrometry (SELDI-
TOF-MS) using the eight-spot format CM10 (weak cationic
exchange) ProteinChip arrays (Bio-Rad). In a preliminary study
performed to set up the experimental conditions, 2 pooled serum
samples from the 9 patients without HCV-RNA recurrence and
the 10 patients included in the training set were loaded onto three
different types of Protein Chip arrays: H50 (that binds proteins
through reverse phase or hydrophobic interactions), CM10
(negatively charged surface that acts as a weak cation-exchanger)
and IMAC-30 (Immobilized Metal Affinity Capture surface
preactivated with copper). The resulting spectra from each pool
were compared and the CM10 array showed the highest number
of peaks detected and the highest total signal intensity compared to
H50 and IMAC-30; therefore only the CM10 array was used in
the subsequent studies. Prior to sample loading, spots were
equilibrated two times with 200 ml of CM binding/washing buffer
(0.1 M sodium acetate, pH 4). Each sample was loaded in
duplicate randomly in order to minimize any systematic error.
Forty microliters of fractionated serum sample was incubated in
60 mL of CM binding buffer for 30 minutes on a shaker at room
temperature. Afterwards, arrays were washed three times with
200 mL CM washing buffer for 5 minutes at room temperature.
Unbound serum proteins were removed by washing twice with
deionized water. Thereafter, arrays were air-dried and 1 mL of
energy-absorbing matrix (saturated sinapinic acid in an aqueous
solution containing 50% acetonitrile and 0.5% TFA) was added
twice to each spot. The surface was allowed to air dry between
each application. The array was read by using the ProteinChip
PBS II reader (BioRad). Each spot was read at low (2500 nJ),
medium (3000 nJ) and high (3500 nJ) energy laser intensities. The
mass-to-charge ratio (m/z) was set from 1.000 to 25.000 m/z for
the low-energy laser intensity, between 2.500 and 200.000 m/z for
the medium-energy laser intensity and from 5.000 to 200.000 for
the high-energy laser intensity. All spectra were calibrated using
two external calibration standards (all-in-one peptide standard and
all-in-one protein standard, BioRad). A peak resolution was
optimized within 5.000 m/z, 12.000 m/z or 19.000 m/z accord-
ing to low, medium or high energy laser intensity, respectively.
Data acquisition and analysis
All data were processed with the ProteinChip Data Manager
Client 4.1 software (Bio-Rad). To minimize the possible random
error and spectral outliers, all the raw data was normalized by the
average total ion current across the group and all spectra differing
by twice the standard deviation or more from the mean were
deleted. Furthermore, the baseline was also corrected by adjusting
the parameter to 30 times the expected peak width. For the peak
selection, several parameters were selected for the identification of
peak clusters. Thus, only peaks with a signal to noise equal or
greater than 5; with a valley depth superior than three; found in a
minimum of 20% of all spectra and with an m/z error below the
0.3% for the low-energy laser intensity spectra and below 2% for
the medium- and high-energy laser intensity spectra, were
considered. Subsequently, all peak clusters detected were verified
manually. Relabeling, removal or addition of peaks was performed
when necessary. To test the quality of the assay, pooled normal
sera from two individuals was assessed. Five protein peaks
randomly selected over the course of the study were used to
calculate the coefficient of variance (CV) as described [7]. We then
determined the reproducibility of the SELDI spectra, both within
and between arrays (intra-assay and inter-assay, respectively). The
intra-assay (spot to spot) CV was 11.95% for peak intensity and
0.02% for mass accuracy. The inter-assay (chip to chip) CV was
21.96% for peak intensity and 0.03% for mass accuracy.
Identification of candidate biomarker
See (Data S2).
Cell Culture
HepG2 cells were obtained from American Type Culture
Collection (ATCC, Manassas, VA, USA). This immortalized,
stable cell line can be repeatedly frozen, thawed and propagated.
HepG2 cells were seeded (26106 cells/well) in vented T-75 flasks
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and grown to confluence in Dulbecco’s Modified Eagle Medium
(DMEM), supplemented with 50 U/ml penicillin, 50 mg/ml
streptomycin and 10% of fetal calf serum (FCS). Thereafter, cells
were switched to 1% FCS and incubated (37uC) under normoxic
(21% O2, 5% CO2) or hypoxic conditions (5% O2, 5% CO2) in a
controlled O2 water-jacketed CO2 incubator (Forma Scientific
Series II, 3131, Marietta, OH) or treated with TNF-a (10 ng/ml,
Sigma, St Louis, MO), lipopolysaccharide (LPS, 10 ng/ml,
Table 1. Baseline characteristics of liver transplant recipients in non recurrent and recurrent hepatitis C patients.
NON RECURRENT
HCV SUBJECTS (n =9)
RECURRENT HCV
SUBJECTS (n =10) P*
Sex (M/F) 7/2 3/7
Age (yr) 53.963.3 55.962.3 NS
Fibrosis score (1 yr after LT)
F 1–2 (n) - 4
F 3–4 (n) - 6
HVPG (1 yr after LT)
HVPG,6 mm Hg (n) - 0
HVPG 6–10 mm Hg (n) - 2
HVPG$10 mm Hg (n) - 5
Bilirubin (mg/dl) 0.960.1 1.360.3 NS
Albumin (g/l) 43.161.1 37.862.1 ,0.05
BUN (mg/dl) 27.463.5 34.063.4 NS
AST (U/l) 28.964.5 152.3647.1 ,0.001
ALT (U/l) 37.766.6 202.7660.9 ,0.001
Total proteins (g/l) 67.961.6 63.163.3 NS
PT(%) 93.262.4 86.363.4 NS
ELF score 9.960.3 11.760.5 ,0.05
*in comparison to non recurrent HCV subjects (Mann-Whitney U test), NS: non significant. Results are given as mean6SEM.
doi:10.1371/journal.pone.0109254.t001
Figure 1. Differential proteomic profile between HCV2 and HCV+ patients submitted to LT. Fragment ranging from 3000 to 11000 m/z
of the differential SELDI-TOF-MS spectra of all serum samples obtained from patients 6 months after LT. The upper figure shows all overlapped
spectra from HCV-negative patients (n = 9). The bottom figure shows the spectra from HCV-infected patients (n = 10). Arrows indicate peaks showing
significantly different intensities between HCV2 and HCV+ patients. Upper letters correspond to the identification peak noted in table 2.
doi:10.1371/journal.pone.0109254.g001
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Sigma), AII (80 pM, Sigma), Endothelin-1 (2 nM, Sigma), Apelin
(100 nM, Phoenix Pharmaceuticals, Burlingane, Ca), Fibronectin
(10 ng/ml, Sigma), Interleukin-1b (20 ng/ml, Sigma) and TGF-b
(10 ng/ml, R&D Systems, Minneapolis, Mn). All experiments
carried out in cell lines were reproduced three times in at least 2
independent assays. Conditioned media were harvested, concen-
trated (80:1) using 3000 MW Amicon Ultra centrifugal filters
(Millipore Corp) and the presence of the fibrinogen a C-chain was
assessed by SELDI-TOF-MS as described above.
Messenger RNA expression of human fibrinogen a, b,
and c chains in HepG2 cells
See (Data S3).
Measurements and statistical analysis
The same day of the liver biopsy, 20 ml of blood were obtained
in a fasting status. Serum was stored at 280uC, and serum
albumin, aspartate aminotransferase (AST), alanine transaminase
(ALT), bilirrubin and blood urea nitrogen (BUN) were measured
with the ADVIA 2400 Instrument (Siemens Healthcare Diagnos-
tics, Tarrytown, NY, USA). Amino-terminal propeptide of type III
procollagen (PIIINP), hyaluronic acid (HA), and tissue inhibitor of
matrix metalloproteinase type-1 (TIMP-1) were measured in all
patients by a CE-marked random-access automated clinical
immunochemistry analyzer that performs magnetic separation
enzyme immunoassay tests (ADVIA Centaur, Siemens Healthcare
Diagnostics, Tarrytown, NY, USA). The enhanced liver fibrosis
(ELF) score was calculated using the algorithm recommended in
the CE-marked assay [ELF = 2.278 + 0.851 ln(HA) + 0.751
ln(PIIINP) + 0.394 ln(TIMP-1)] blood tests.
Statistical analysis of the results was performed by the non
parametric Mann-Whitney U test and the Kruskal-Wallis test with
the Dunn post hoc test as appropriated. Quantitative data were
analyzed using GraphPad Prism 5 (GraphPad Software, Inc. San
Diego, CA).
Ethics Statement
We obtained written informed consent from all patients
included in the study and the investigation was approved by the
Investigation and Ethics Committee of the Hospital Clinic of
Barcelona following the ethical guidelines of the 1975 Declaration
of Helsinki.
Results
Mass Spectrogram of LT patients with early fibrosis
recurrence significantly differs from that of non recurrent
LT patients
The principal demographic values of patients included in the
definition group are shown in Table 1. As per the selection
criteria, most recurrent HCV patients showed higher fibrosis and
ELF scores, elevated HVPG measures and greater AST and ALT
values than non recurrent HCV subjects. Figure 1 depicts a
portion of the spectra of all the samples investigated in this training
group, ranging between 3000 and 11000 Daltons; the mass to
charge ratio analyzed. The expression pattern of the spectrograms
obtained from non recurrent HCV patients clearly differed from
those of recurrent HCV subjects. Six statistically different peaks,
identified in the figure as peptides A, B, C, D, and E, were
detected. As shown in Table 2 the signal intensity of four of these
peaks (A, B, C, and F) was markedly higher in non recurrent than
in recurrent patients whereas an inverse situation was observed in
the remaining two peaks (D and E). The most remarkable
difference was detected on analyzing peptide A (5905 m/z), since
it was fully evident in all samples obtained from non recurrent
HCV patients but almost suppressed in the serum of recurrent
HCV individuals.
Neither LT nor HCV infection account for Mass
Spectrogram differences in patients with active
fibrogenesis
An intriguing question arising from the above described results
was to elucidate whether these findings result from the particular
characteristics of HCV transplanted patients rather than to a
differential feature characterizing early fibrogenic processes. Thus,
the serum proteomic spectrum was next analyzed in healthy
individuals, in non-LT fibrotic HCV infected patients and in non
HCV fibrotic patients. The clinical and demographic character-
istics of these subjects are shown in table 3. Fibrosis scores and
liver function tests of the two groups of fibrotic patients were
similar to those obtained in HCV LT patients. The mass
spectrograms of all individuals included in this portion of the
investigation are shown in figure 2. The upper, middle and lower
parts correspond to healthy subjects, fibrotic non HCV subjects
and fibrotic HCV patients, respectively. Since in the previous
experiments the most striking differences were observed with
peptide A, in this and the subsequent experiments we focused on
the peak with a mass/charge ratio of 5905 Da. All serum samples
analyzed from healthy subjects showed a spectrogram compatible
with the presence of this peptide whereas pathological serum
Table 2. Intensity values (mA) of peaks showing different patterns of expression in the two groups of patients.
PEPTIDE m/z (Da)
NON RECURRENT
HCV SUBJECTS (n =9)
RECURRENT HCV
SUBJECTS (n =10)
A 5905 257.1643 5.9963.49d
B 6639 687.4696.3 176.8632.5c
C 6845 71.968.9 27.1365.42b
D 8144 76.9622.5 392.8664.8d
E 9172 15.166.4 26.0363.37a
F 12986 6.661.2 1.9960.41a
ap,0.05, bp,0.01, cp,0.001, dp,0.0001; in comparison to non recurrent HCV subjects (Mann-Whitney U test). Results are given as mean6SEM.
doi:10.1371/journal.pone.0109254.t002
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samples, either from fibrotic non LT HCV patients or fibrogenic
non HCV subjects showed the absence of this peptide or very low
intensity peaks. These results indicate that neither HCV nor LT
account for the suppressed expression of the A peptide in serum
samples of fibrotic patients.
The Mass Spectrogram of most HCV infected patients
lacks a 5.9 kDa fragment
To further confirm that peptide A behaves as an early serum
biomarker of fibrosis, mass spectrometric analysis was performed
in a test group of serum samples obtained from 83 HCV recurrent
patients 6 months after LT. HVPG was assessed in 53 of these
patients and the average value was of 5.560.8 mm Hg. All the
serum samples showed a quite similar expression pattern and
coincidences included both the different peptide fragments
detected and the signal intensity of these fragments (Data S4).
The most relevant finding was, however, that the mass spectrum
corresponding to peptide A showed a very low peak intensity in all
samples obtained from HCV recurrent patients. In fact, in 53 out
of the 83 patients the peak intensity at m/z 5905 was under the
background levels of 10 mA and in the remaining samples,
intensities ranged between 11.5 and 81.4 mA (figure 3). Thus,
these results confirm the findings obtained in the training group in
a larger group of subjects.
The 5.9 kDa protein is a C-terminal fragment of the
fibrinogen a chain
To isolate the protein of interest and to determine candidate
protein identity, serum samples from two healthy subjects
containing high SELDI intensity were pooled and separated by
tricine-SDS-PAGE (figure 4B). The band at 5.9 kDa was excised
trypsinized and analyzed by LC-MS/MS. As shown in figure 4C,
two peptide sequences were identified, which matched with the
human fibrinogen a C-chain at 3.23% coverage, suggesting that
suppression of the fibrinogen a C-chain 5.9 kDa fragment is an
early surrogate indicative of active fibrogenesis in patients with
liver disease.
TGF-b reduces the expression of the fibrinogen a chain
but not of the b and c chain in HepG2 cells assays
To unveil potential mechanisms governing the release of the
5.9 kDa peptide C-terminal fragment of the fribrinogen a chain in
the serum of patients under an early fibrogenic process, HepG2
cells were treated with well known proinflammatory stimuli (TNF-
a, LPS and Il-1b) or profibrogenic substances (AII, ET-1, Apelin,
Fibronectin and TGF-b) for 6 hours. With the exception of TGF-
b, none of these substances induced significant changes in the
expression of human fibrinogen chains messenger. However,
Figure 2. Lack of the 5.9 kDa protein peak in non-LT fibrotic patients. Portion of the SELDI-TOF-MS spectra comprised between 3000 and
11000 m/z of serum samples obtained from healthy subjects (n = 16) and patients with liver fibrosis of several etiologies (NASH, ALD, cryptogenic, AH,
HBV and HCV). The lack of the protein peak at m/z 5905 is clearly associated with fibrogenesis regardless of its etiology.
doi:10.1371/journal.pone.0109254.g002
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TGF-b markedly reduced the expression of the a chain in cultured
human hepatocytes. As shown in figure 5, this phenomenon was
specific for the a chain since no significant changes were observed
on analyzing the b and c chain messengers. In addition, culture
media of cells treated with TGF-b displayed diminished
abundance of the 5.9 kDa fragment of the fibrinogen a C-chain
in comparison to untreated cells.
Table 3. Baseline characteristics of healthy subjects and HCV-infected and non-infected fibrotic patients.
HEALTHY SUBJECTS (n =16) HCV INFECTED PATIENTS (n=8) NON INFECTED FIBROTIC PATIENTS (n =33)
Sex (M/F) (9/7) (5/3) (19/14)
Age (yr) 35.662.5 48.763.6 52.362.4***
Fibrosis score
F 1–2 (n) - 2 11
F 3–4 (n) - 6 22
Etiology
HCV (n) - 8 -
HBV (n) - - 3
NASH (n) - - 9
ALD (n) - - 10
AH (n) - - 4
Cryptogenic (n) - - 7
Bilirubin (mg/dl) 0.660.1 0.560.06 1.260.2*,b
Albumin (g/l) 41.061.5 42.960.6 40.961.2
BUN (mg/dl) 15.262.1 14.461.6 18.162.2
AST (U/l) 20.961.6 64.067.9*** 56.366.6***
ALT (U/l) 15.962.3 82.168.8*** 79.1615.4***
Total proteins (g/l) 71.361.2 78.662.3 75.461.7
PT(%) 96.560.9 89.863.1 86.462.4*
ELF score 8.660.4 9.660.6 9.760.2
INR 1.0060.01 1.0460.03 1.1060.03
*p,0.05, ***p,0.001 in comparison to healthy subjects and bp,0.01 in comparison to HCV infected patients (Kruskal-Wallis test with the Dunn pos hoc test). Results
are given as mean6SEM.
doi:10.1371/journal.pone.0109254.t003
Figure 3. Comparison of the 5.9 kDa protein peak intensity between all the groups analyzed. SELDI-TOF-MS intensity values of the
5.9 kDa peak of the different groups of patients studied. Intensity of the peak was markedly suppressed in all patients under an active fibrogenic
process.
doi:10.1371/journal.pone.0109254.g003
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Discussion
Evaluation of the extension and aggressiveness of the fibrogenic
process in the injured liver is of major relevance for the diagnosis,
prognosis and treatment of patients with hepatic disease [8]. The
methods currently available to assess liver fibrosis include the
serological determination of several parameters related to liver
function and hepatic remodeling, imaging techniques, such as
Fibroscan or ARFI and the use of invasive procedures such as
HVPG measurement or liver biopsy, the latter still being the most
widely accepted gold standard method for assessing liver fibrosis
[9]. The specific limitations of each of these methods have been
extensively discussed previously [10]. The risk of complications
and low sensitivity for mild or moderate fibrosis are among the
most remarkable limitation for invasive and non invasive methods,
respectively [11]. Recently, a liver fibrosis score, namely ELF,
which combines the serum concentrations of substances related to
collagen metabolism (PIIINP) and tissue remodeling (TIMP-1 and
HA), has progressively been incorporated among the most
common diagnostic tools to evaluate liver fibrosis. However,
whereas this technique was found to be highly accurate in patients
with advanced fibrosis (F3–F4 stage) [12–14] it appeared to be less
efficacious in the diagnosis of mild or moderate fibrosis (F1–F2
stage) [15,16]. Early detection of active fibrogenic activity,
therefore, still remains an open challenge in liver disease.
Fibrosis progression evolves over long periods of time, with this
representing one of the most relevant difficulties to identify specific
early biomarkers of fibrosis. In the current investigation this issue
was overcome by assessing the proteomic profile of HCV-positive
LT recipients in a training set of serum samples. Blood samples
were obtained at 6 months after LT and a liver biopsy was
performed 1 year after surgery to define fibrosis stage. It is well
known that fibrosis progression is accelerated in recurrent hepatitis
C, with 15% to 47% of LT recipients developing fibrosis/cirrhosis
within the first 3 years post transplantation [17]. Therefore, rapid
fibrosis progression is a major characteristic of this group of
patients and for this reason they are particularly suitable to
uncover serum tags of hepatic fibrosis.
SELDI-TOF-MS technology or protein chip profiling combines
mass spectrometry with a surface enhanced biochip which allows
uniform and reproducible binding and desorption of biomarkers
[18]. SELDI-TOF-MS also incorporates sample prefractionation.
This markedly decreases the complexity of protein rich fluids, such
as serum, allowing comparison of peak intensity between samples
using large sample sets [19]. In the current study, serum proteins
were fractionated by anion exchange chromatography based on
their isoelectric points using a pH gradient. The resulting fraction
Figure 4. Isolation, separation and identification of the 5.9 kDa protein peak. A/ Spectra obtained by SELDI-TOF-MS showing the isolated
protein peak after the purification process. B/ The isolated band indicated with arrows, after running two tris-tricine gels, one stained with sypro (I)
and the other with oriole (II) staining. C/ Fragment of the Fibrinogen a-Chain identified as the differential protein peak by the amino acid sequencing.
The two sequences identified are shown in bold.
doi:10.1371/journal.pone.0109254.g004
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was bound to a weak cation exchange surface to create an array of
Protein Chip spots. This surface was selected according to its
higher accuracy and reproducibility yields. Using this technology
we were able to simultaneously detect relative protein expression
levels over a range of molecular masses of 2 to 180 kDa, although
the 2–20 kDa range appeared to be the most sensitive. By means
of this profiling system, we found at least 6 serum biomarkers that
were differentially increased or decreased in recurrent HCV
patients. Among them, a protein of 5.9 kDa (protein A) was fully
suppressed in the serum of all the HCV patients included in the
training set. In contrast, readily detectable levels of this protein
were detected in all non-recurrent HCV patients. We assessed
whether LT and/or HCV infection account for the different
expression patterns of peak A in serum samples of non-
transplanted HCV positive and HCV negative subjects with
fibrosis. The demographic and biochemical characteristics of
patients with fibrosis included in the training set of samples were
quite similar to those displayed by the fibrotic patients of this
protocol with the exception of hepatic enzymes which, as
expected, were higher in LT recurrent HCV patients than in
fibrotic non-transplant patients. Both, the proteomic profile of the
HCV positive samples and the proteomic profile of fibrotic
patients non-infected sera, showed no or very low intensity peaks
at the 5.9 kDa spectra. This markedly differed from the proteomic
analysis of the serum samples of healthy subjects included in this
set of experiments because all displayed consistent amounts of
protein A. Interestingly, different etiologies (NASH, ALD, HBV,
AH, cryptogenic) accounted for liver fibrosis in negative HCV
patients, further emphasizing the close relationship between the
lack of the 5.9 kDa protein and the fibrogenic process.
Next, the spectral data obtained in the test set were applied for
validation purposes. All serum samples included in the test set
showed an intensity m/z 5905 peak well below the values found in
both healthy subjects and non recurrent HCV patients. Indeed, in
most of these samples the A peak was not detected (figure 3).
Overall, our results showing markedly decreased expression of the
m/z 5905 in the spectral profile of all samples from patients with
fibrosis further strengthen the highly sensitive diagnostic perfor-
mance of this peak.
A major limitation of SELDI-TOF-MS technology is related to
the unfeasibility of directly identifying the protein of interest. In
fact, for the majority of protein identifications it is necessary to
achieve the enrichment of the specific peak by chromatography
procedures and purification by SDS gel electrophoresis with
subsequent triptic digest. In our investigation, amino acid
sequencing of the trypsin digest of the 5.9 kDa protein revealed
it to be a fragment of the fibrinogen a C-chain. Human fibrinogen
is a circulating 340 kDa glycoprotein which has been shown to be
of hepatic origin in vivo. Moreover, inflammatory stimuli may
induce in vitro secretion of this glycoprotein in non hepatic cells
including epithelial cells, granulosa cells, cervical carcinoma cells
and trophoblasts [20]. However, current evidence strongly
suggests that the largest site of human plasma fibrinogen is the
hepatocytes [21]. It is comprised of two symmetric half molecules
bound by a disulphide knot, each consisting in one set of three
different polypeptide termed Aa, Bb and c. Each of these
polypeptides is encoded by a separate gene located on chromo-
some four. The predominant Aa of circulating fibrinogen contains
610 aa (63.5 kDa), the Bb chain 461 aa (56 kDa) and the c chain is
heterogeneous, but the most abundant form consists of 411 aa
(48 kDa). The protein shows extensive post translational modifi-
cation including phosphorylation, sulphation, glycosylation and
hydroxylation. The fibrinogen a C-domain of the human
fibrinogen is the C-terminal two-thirds of the Aa chain that
extends from the coiled oil portion of each half of the dimeric
fibrinogen molecule [22,23]. The a C-fragments are released into
circulation as natural by-products of fibrinolytic systemic activa-
tion and are therefore, found in the systemic circulation in healthy
individuals [24]. Our results showing almost suppressed expression
of the 5.9 kDa fragment of the a C-chain of fibrinogen in patients
undergoing a fibrogenic process are in agreement with those
previously reported by Nomura F et al in heavy drinkers [25].
Figure 5. TGF-b reduces the fibrinogen a-chain expression in HepG2 cells. Fold regulation in Fibrinogen Alpha Chain (FGA), Beta Chain
(FGB) and Gamma Chain (FGG) genes regulation in HepG2 cells after 6 hours of treatment with TGF-b (10 ng/ml). Results are given as mean 6 SE;
***p,0.001 vs. basal. Statistical analysis was calculated by unpaired Student’s t test. The insert shows the intensity values of the 5.9 kDa peak
detected in the cellular supernatant of HepG2 cells after 48 hours of treatment with TGF-b (10 ng/ml). Results are given as mean 6 SE; *p,0.05 vs.
basal. Statistical analysis was calculated by Mann-Whitney U test.
doi:10.1371/journal.pone.0109254.g005
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Furthermore, these authors showed that serum levels of this
fragment were recovered when alcohol intake has ceased for more
than 3 months and they also extended their findings to HCV
infected patients [26]. Later, this fragment was described as having
diagnostic value in patients with acute respiratory syndrome [27],
breast cancer [28] and pancreatic adenocarcinoma [29].
The regulation of total human fibrinogen by a number of
proinflammatory agents has been previously investigated using the
HepG2 hepatocellular carcinoma cell line [30]. This in vitro
model faithfully recapitulates fibrinogen expression including a, b
and c fibrinogen [31] and has been used to study fibrinogen
production and regulation in vitro [32]. Accordingly we subse-
quently assessed the potential regulatory role of several candidate
mediators on a-fibrinogen expression in HepG2 cells. A number of
proinflammatory/profibrogenic agents that have previously been
involved in the pathogenesis of the fibroproliferative processes
[33–35] were tested. Among them, only TGF-b showed significant
regulatory activity on a-fibrinogen mRNA expression and
decreased 5.9 kDa fibrinogen aC-fragment intensity. Of note
was, however, that the fold change in the fibrinogen aC-fragment
induced by TGF-b in HepG2 cells was makedly lower than that
observed in samples from fibrotic patients. The marked differences
between the in vivo and in vitro experimental conditions likely
account for this discordance. For instance, HepG2 is a human
derived carcinoma cell line that shows altered abundance of TGF-
b receptors [36,37] which in turn could result in some sort of
resistance to this cytokine. On the other hand it is well known that
regulation of acute-phase proteins is mediated by a combination of
cytokines thus raising the possibility that additional factors
involved in inflammatory processes also regulate the expression
of the 5.9 kDa fragment of fibrinogen [38]. Our results are in line
with past studies in which TGF-b inhibited the induction of
fibrinogen produced by IL-6 and decreased the synthesis of
fibrinogen in HepG2 and HepB cells [38], respectively. These
latter experiments also showed a parallel diminution in a-
fibrinogen mRNA levels. This phenomenon seems to be mediated
by post-transcriptional mechanisms since TGF-b did not modify
fibrinogen gene transcription, suggesting that the effect of this
cytokine in liver cells is regulated at the level of mRNA stability
[39]. Overall, all these results indicate that TGF-b may regulate
the synthesis of a-fibrinogen at the postranscriptional level.
In summary, the current investigation took advantage of the
faster development of hepatic fibrosis in HCV-positive LT patients
to identify early circulating serum biomarkers of active fibrogenesis
in patients with liver disease. Using high throughput SELDI-TOF-
MS technology we unveiled a differential protein pattern profile
between early fibrosis recurrence and non recurrent LT patients.
Six protein peaks displaying statistically significant different
intensities were observed within a range of 1000 to 25000 m/z.
The peak located at 5905 m/z showed the most remarkable
difference, since it was fully detected in non-recurrent LT patients
but was almost suppressed in recurrent LT patients. Similar results
were found when comparing samples of healthy subjects with
those of non LT fibrotic patients both HCV positive and negative,
indicating that our findings were not related to either LT or HCV
infection. Identification of this protein peak showed more than a
99% coincidence with a C-terminal fragment of the fibrinogen a
chain. Moreover, cell culture experiments demonstrated that
TGF-b downregulates a-fibrinogen mRNA expression and
decreases the peak intensity of the m/z 5.9 KDa protein in
HepG2 cells. In conclusion, we identified a 5.9 kDa C-terminal
fragment of the fibrinogen a chain as a serum biomarker of early
fibrogenic processes in patients with liver disease. Since TGF-b
inhibited a-fibrinogen mRNA expression in HepG2 cells it is
temptative to speculate that the activation of this cytokine in the
early phases of liver injury could be responsible for the impairment
in the circulating levels of the fibrinogen a C-chain fragment in
patients with active hepatic fibrogenesis.
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